Saab Jad, Santos-Zabala Maria Laureana, Loda Massimo, Stack Edward C, Hollmann Travis J
Memorial Sloan Kettering Cancer Center, New York, NY.
CBLPath, Rye Brook, NY.
Am J Dermatopathol. 2018 Apr;40(4):259-264. doi: 10.1097/DAD.0000000000000939.
Melanoma is a potentially lethal form of skin cancer for which the current standard therapy is complete surgical removal of the primary tumor followed by sentinel lymph node biopsy when indicated. Histologic identification of metastatic melanoma in a sentinel node has significant prognostic and therapeutic implications, routinely guiding further surgical management with regional lymphadenectomy. While melanocytes in a lymph node can be identified by routine histopathologic and immunohistochemical examination, the distinction between nodal nevus cells and melanoma can be morphologically problematic. Previous studies have shown that malignant melanoma can over-express metabolic genes such as fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC). This immunohistochemical study aims to compare the utility of FASN and ACC in differentiating sentinel lymph nodes with metastatic melanomas from those with benign nodal nevi in patients with cutaneous melanoma.
Using antibodies against FASN and ACC, 13 sentinel lymph nodes from 13 patients with metastatic melanoma and 14 lymph nodes harboring benign intracapsular nevi from 14 patients with cutaneous malignant melanoma were examined. A diagnosis of nodal melanoma was based on cytologic atypia and histologic comparison with the primary melanoma. All nodal nevi were intracapsular and not trabecular. Immunohistochemistry for Melan-A, S100, human melanoma black 45 (HMB45), FASN, and ACC were performed. The percentage of melanocytes staining with HMB45, FASN, and ACC was determined and graded in 25% increments; staining intensity was graded as weak, moderate, or strong.
All metastatic melanomas tested had at least 25% tumor cell staining for both FASN and ACC. Greater than 75% of the tumor cells stained with FAS in 7/13 cases and for ACC in 5/12 cases. Intensity of staining was variable; strong staining for FASN and ACC was observed in 69% and 50% of metastatic melanoma, respectively. HMB45 was negative in 40% of nodal melanoma cases all of which stained with FASN and ACC. Capsular nevi were uniformly negative for FASN, ACC, and HMB45 immunoreactivity.
All metastatic melanoma cases involving sentinel lymph nodes were positive for FASN and ACC while no staining was observed in intracapsular nevi. These findings suggest that FASN and ACC could be used as valuable ancillary stains in the distinction between nodal nevi and metastatic melanoma.
黑色素瘤是一种潜在致命的皮肤癌,目前的标准治疗方法是完整手术切除原发性肿瘤,如有指征则随后进行前哨淋巴结活检。前哨淋巴结中转移性黑色素瘤的组织学鉴定具有重要的预后和治疗意义,通常指导进一步的手术治疗,即进行区域淋巴结清扫术。虽然淋巴结中的黑素细胞可通过常规组织病理学和免疫组织化学检查来识别,但淋巴结痣细胞与黑色素瘤之间的鉴别在形态学上可能存在问题。先前的研究表明,恶性黑色素瘤可过度表达脂肪酸合酶(FASN)和乙酰辅酶A羧化酶(ACC)等代谢基因。本免疫组织化学研究旨在比较FASN和ACC在鉴别皮肤黑色素瘤患者的前哨淋巴结转移性黑色素瘤与良性淋巴结痣方面的效用。
使用抗FASN和ACC的抗体,对13例转移性黑色素瘤患者的13个前哨淋巴结以及14例皮肤恶性黑色素瘤患者的14个含有良性囊内痣的淋巴结进行检查。淋巴结黑色素瘤的诊断基于细胞学异型性以及与原发性黑色素瘤的组织学比较。所有淋巴结痣均为囊内痣,而非小梁状。进行了Melan-A、S100、人黑色素瘤黑色45(HMB45)、FASN和ACC的免疫组织化学检测。确定用HMB45、FASN和ACC染色的黑素细胞百分比,并以25%的增量进行分级;染色强度分为弱、中或强。
所有检测的转移性黑色素瘤中,FASN和ACC的肿瘤细胞染色率均至少为25%。13例中有7例FAS染色的肿瘤细胞超过75%,12例中有5例ACC染色的肿瘤细胞超过75%。染色强度各不相同;分别有69%和50%的转移性黑色素瘤观察到FASN和ACC的强染色。40%的淋巴结黑色素瘤病例HMB45为阴性,所有这些病例均对FASN和ACC染色。囊内痣对FASN、ACC和HMB45免疫反应均呈阴性。
所有累及前哨淋巴结的转移性黑色素瘤病例FASN和ACC均呈阳性,而囊内痣未观察到染色。这些发现表明,FASN和ACC可作为区分淋巴结痣和转移性黑色素瘤的有价值的辅助染色剂。